Quantification of the HIV viral reservoir is critical to understanding HIV latency, advancing patient care and ultimately achieving a cure. To quantify the reservoir, a new metric was recently introduced, which quantified cells carrying multiply spliced HIV RNA. The developed assay, Tat/rev Induced Limiting Dilution Assay (TILDA), enables quantification of cells containing multiply-spliced HIV RNA events as an indicator of reservoir size. Due to TILDA's reliance on a limiting dilution format paired with the rarity of target events, numerous individual reactions are required to obtain a single endpoint. The current assay embodiment uses a whole cell input to detect target RNA sequences without the traditional preceding nucleic acid purification steps. Thus, while the direct measurement of target events from whole cells significantly streamlines the workflow, there is a cost in sensitivity and assay throughput. Here, we apply a new technique for rapid RNA isolation, ExclusionBased Sample Preparation, to TILDA, with the goal of alleviating these limitations without significantly adding to the workflow. By combining TILDA with multiplexed RNA extraction enabled by exclusion-based sample preparation, assay sensitivity and capacity are improved while maintaining assay simplicity, advancements that could facilitate eventual clinical implementation in detecting rare events in patients.
Introduction
Recent HIV treatment strategies have largely succeeded in containing HIV progression while greatly reducing the risk of death from AIDS. [1] [2] [3] [4] Yet, eradication of the virus is not yet possible as integration of HIV into the host cell genome throughout the course of infection leads to the establishment of a viral reservoir. [5] [6] [7] [8] Termed the latent HIV reservoir, the reservoir serves as an 'underground spring' capable of replenishing virus production even after years of undetectable viral load measurements. 9 While the reservoir is widely accepted as a major barrier to HIV eradication, metrics to quantify and monitor the reservoir remain debated; furthermore, there is no FDA-approved assay for quantifying the reservoir, limiting clinical implementation of reservoir-based cure strategies. Until recently, reservoir quantification centered around two targets: (1) HIV DNA and (2) host cells capable of producing replication competent virus. HIV DNA occurs in cells infected with HIV, as HIV reverse transcribes its RNA genome into DNA shortly after infection. Assays measuring HIV DNA provide a fast, relatively simple PCR-based reservoir quantification. For additional specificity, many have adopted Alu-PCR, designed to limit detection to HIV DNA that has integrated into the host genome, one step further in the infection process. Despite the assay's relative simplicity, the relevance of HIV DNA, either a Department of Biomedical Engineering, Wisconsin Institutes for Medical Research, total or integrated (e.g., Alu-PCR), is unclear. 10 The detection of HIV DNA does not guarantee a cell will actively contribute to the reservoir (i.e., be able to produce HIV capable of infecting other cells). HIV DNA does not ensure a cell's downstream ability to produce virus (improper integration, ineffective integration sites, etc.) nor ensure the produced virus' infectiousness, two key components in contributing to the reservoir. Thus, HIV DNA is suspected to overestimate the size of the reservoir. 10 In contrast, the Quantitative Viral Outgrowth Assay (QVOA) aims to quantify only events that lead to the production of infectious virus, making it highly specific. However, QVOA requires extensive sample volume, time, and expertise to co-culture and propagate the virus to a detectable level, limiting widespread use. A recent iteration of this assay was able to decrease culture time; 11 yet significant hurdles remain. Despite QVOA's utility as a critical research tool and incremental improvements, QVOA's limited sensitivity and laborious protocols as well as shortcomings in reproducibility, and dynamic range continue to prohibit widespread utilization. While both assays have expanded knowledge of the HIV reservoir, a niche exists between them for an assay, which maintains the simplicity of PCR-based approaches, but improves on the specificity of detected events. Recently, Procopio et al. (2015) introduced a new metric and method to quantify the HIV viral reservoir: Tat/rev Induced Limiting Dilution Assay (TILDA). TILDA detects the presence of cellular tat/rev multiply-spliced HIV RNA (tat/rev msRNA) as an early indicator of HIV production. [12] [13] [14] [15] [16] [17] [18] As numerous defective HIV genomes often have modifications in the tat and rev genes, 19 the presence of tat/rev msRNA has been shown to be an early indicator of cells capable of producing functional, infectious virus. To detect tat/rev msRNA, TILDA begins with patient cell induction (e.g., PMA) throughout a 12 hour culture to reverse latency, and induce the cells to begin producing HIV-related mRNA transcripts, including the target tat/rev msRNA. To detect tat/rev msRNA, TILDA directly inputs the raw whole cells into the reverse transcription reaction, directly followed by a nested PCR reaction to amplify sequences specific to tat/rev msRNA. By detecting tat/rev msRNA, TILDA fills a gap between existing reservoir assays -integrated HIV DNA, considered as an overestimate of the viral reservoir, and QVOA, an assay that requires extensive sample volume, expertise, time, and cost. While TILDA remains yet untested in terms of its clinical implications and relevance in monitoring the reservoir in patients, TILDA is well formatted for clinical adoption. Yet, additional improvements are required to bring TILDA into the clinic. While TILDA holds great potential, TILDA faces limitations, which hinder clinical adoption and widespread use. Currently, TILDA's utilization of whole cell inputs, rather than purified RNA, results in a simplified assay, without the need for traditionally laborious RNA isolations prior to downstream detection. However, while a whole cell input provides TILDA with simplicity, assay input material (e.g., purity, quantity, quality) ultimately impacts RT-PCR outcomes. [20] [21] [22] As a result, TILDA's whole cell input is detrimental to the RT-PCR reaction, extending assay time, impairing sensitivity, and ultimately limiting the number of cells screened. In quantifying the reservoir, the rarity of positive events, require an assay best able to capitalize both on capacity and sensitivity. Furthermore, as treatments aiming to deplete the reservoir enter clinics, the assay will need to screen an increasing number of cells in each patient as the reservoir is depleted beyond the existing limit, ideally by simply increasing the number of events screened within the assay. In contrast to whole cells, isolated RNA provides a purified input material with limited background to amplify (i.e., RNases, inhibitors, proteins). However, the integration of RNA extractions into TILDA requires an easily multiplexed approach enabling parallel RNA extractions in order to fit into the existing assay, maintain the assay's simplicity, and support the large number of independent isolations. Manual magnetic bead approaches to RNA extraction require multiple laborious washing steps, in which the buffer is mixed with the RNA-specific paramagnetic particles (PMPs), the PMPs allowed to collect on a magnetic rack, then the fluid removed over the course of multiple washes. While automation can alleviate some of the hands-on time, these systems remain expensive and, due to the number of extractions required by TILDA, would likely be monopolized for a single patient sample making throughput a bottleneck in these systems. In brief, cells were counted and then loaded in the bottom of a 96-well plate (o5 mL volume). Lysis Binding Buffer (Dynabeads mRNA Direct, Thermo Fisher) with 15 mL oligo (dT) 25 paramagnetic particles (PMPs) (Dynabeads mRNA Direct, Thermo Fisher), and 3 mL of Magnesil KF PMPs (Promega) were then added to each well in a volume of 150 mL, mixed, and allowed to lyse for 10 minutes. After 10 minutes, the well volume was brought to 410 mL with Wash Buffer B (Dynabeads mRNA Direct, Thermo Fisher) and re-mixed. Using a bar magnet (or 8 individual magnets in the automated platform) protected by a hydrophobic barrier (automated platform used EXTRACTMAN Bead Capture Strip (Gilson); manual RNA platform used a plastic film (Roche LightCycler s 480 Sealing Foils)). PMPs were collected at the surface of the well by hovering the collection surface backed by a bar magnet (or magnetic head in the automated platform) above the wells, allowing the PMPs to collect on the surface. The collection surface, now containing the PMPs and bound RNA were moved away from the lysis well and over a wash well prefilled with 415 mL of Wash Buffer B. The wash buffer formed a convex drop at the top of the well allowing the collection surface containing the PMP pellets to come in direct contact with the fluid. The magnet was then removed from the strip and placed below the plate. Due to the new position of the magnet below the plate, the PMPs pulled off of the strip and into the wash fluid towards the magnet. Once the PMPs had released in the wash well, the magnet was removed from the bottom of the plate and the PMPs were mixed by multi-channel pipette.
The washed PMPs and bound RNA were then collected on a new collection surface using a magnet again positioned at the top of the well. The collected washed PMPs and bound RNA were then resuspended in 5 mL nuclease-free water and added into a PCR plate filled with complete pre-mixed master mix.
TILDA
Either the whole cell or RNA input was distributed in a PCR plate along with one-step RT-PCR master mix (Taqman Fast Virus 1-Step Master Mix, ThermoFisher), and the previously Step-by-step schematic demonstrating RNA isolations using ExclusionBased Sample Preparation. The process can easily be performed on sets of 8-wells using a bar magnet, a standard 96-well plate, and multichannel pipette, with no additional time over a single RNA isolation in this format (B). 
Results

Integration of Exclusion-Based Sample Preparation RNA isolation
Despite the simplicity of whole cells, a purified RNA input, if easily integrated, could reduce background to improve amplification kinetics, remove potential inhibitors, and ultimately enhance sensitivity and assay capacity (Fig. 1A) . [20] [21] [22] However, due to TILDA's reliance on a large number of individual reactions, traditional RNA extraction methods remain largely incompatible and unrealistic to readily integrate. Previously, a PMP isolation approach termed Exclusion-Based Sample Preparation (ESP) was developed as a means to perform simple PMP-based extractions, which deviated from traditional tube-based approaches (i.e., remove the PMPs from solution rather than remove the fluid from the PMPs). Building off of the ESP core technology, a multiplexed 96-well RNA extraction format was adapted and developed for this application (Fig. 1B) . In this ESP embodiment, RNA extractions were performed in parallel sets of eight, requiring no additional time compared to a single extraction.
To isolate RNA, cells were loaded into a 96-well plate while RNA lysis buffer and RNA binding PMPs were added by multichannel across the plate. Once lysed, the well volume was increased until the concave meniscus on the fluid became convex (B400 mL). A bar magnet, the same width of the plate, was then covered with a removable hydrophobic film and held directly over the first column of samples and positioned so the film just contacted the top of the convex droplet. The PMPs, attracted by the magnet, collected on the film. Once collected, the film, now containing a PMP pellet from each well (up to eight RNA isolations), was then held over a new plate similarly filled with wash buffer. The magnet backing was removed from the film and placed below the wash plate. Once the PMP pellets made contact with the convex fluid, the PMPs were pulled into the wash wells by the magnet below the plate. The PMPs in each wash well were then simultaneously mixed by multichannel pipette. After the PMPs and bound RNA were mixed, a new film was placed on the magnet and the PMPs collected onto its surface. The film was then removed and the magnet backing displaced. Each PMP pellet could then be resuspended with mastermix and loaded into a PCR plate.
Whole cell versus RNA TILDA provides a method for detection of tat/rev msRNA, as a new quantitative metric of the HIV viral reservoir. In the published assay, whole cells were directly utilized as the assay input to detect tat/rev msRNA, without prior purification or isolation of the target analyte, RNA. While the omission of RNA extraction results in a simple assay, we hypothesized whole cell inputs ultimately impair detection of tat/rev msRNA (i.e., due to limited access to target RNA within cells, presence of background material, inhibitors, RNases, etc.) (Fig. 1A) . Using Exclusion-based sample preparation to perform multiplexed PMP-based RNA isolations for parallel RNA extractions (Fig. 1B) , the potential gains in RNA rather than whole cell TILDA were evaluated. To compare inputs, low cell number samples of two HIV-infected cell lines (o10 cells per reaction) known to be positive for tat/rev msRNA were utilized as either whole cells or ESP-extracted RNA.
Previously, these cell lines demonstrated constitutive production of HIV in culture, even at low cell numbers (as detected by viral RNA isolation from conditioned media -see ESI, † Fig. S1 ).
Utilizing a highly idealized sample (consisting of low quantities of cell expressing tat/rev msRNA), both whole cell and ESP RNA inputs resulted in detection of tat/rev msRNA (ESI, † Fig. S2 ) under the published thermocycling conditions (4 minute elongation cycles). However, the published whole cell TILDA 23 ultimately employs atypically long elongation cycles (4 minutes) in contrast to the manufacturer's recommended conditions resulting in a longer assay with added equipment usage (manufacturer recommends elongation cycles of 30 seconds as opposed to 4 minutes); by reducing elongation time from 4 minutes to 30 seconds, 84 minutes of thermocycling time are eliminated from the process. We hypothesized an isolated RNA input would improved detection of rare events over a whole cell input as well as enable detection under standard PCR thermal cycling conditions. In reducing elongation cycling times to 30 seconds, signal was significantly reduced (410 000 fold) in the whole cell inputs ( Fig. 2A) , resulting in missed detection in a number of replicates while ESP RNA inputs maintained detection. Even a highly positive sample for tat/rev msRNA lacking background cells (HIV-negative cells), shortened elongation cycles create detection limitations for whole cell inputs, an issue which is only likely to worsen as (realistic) background is introduced. By implementing ESP-based RNA, the purified sample input enables a reduced elongation time (30 seconds) incompatible with a whole cells input, significantly accelerating time-toanswer ( Fig. 2A) .
Accelerating assay readout
When evaluating a patient sample for tat/rev msRNA, TILDA relies on the detection of rare, target events from a large, varied background across range of cell quantities. To integrate and evaluate the impact of increasing background cell number on a whole cell TILDA, either 10 ACH-2 cells or 10 J1.1 cells were spiked into different quantities of background cells (e.g., healthy PBMCs) and detected using whole cell TILDA under the previously published assay (i.e., 4 minute elongation cycles). Results demonstrate, as background increases, the positive detection of tat/rev msRNA is delayed, despite the equivalent number of detection events across samples (Fig. 2B) . While tat/rev msRNA is readily detectable in the absence of background, detection sensitivity decays as more and more background cells are introduced. Based on the improved signal ESP-isolated RNA provided in reducing thermocycling conditions, the impact of an ESP RNA input, rather than a whole cell input, was tested to evaluate whether a RNA input would recover the signal decay observed with increasing background with a whole cell input (Fig. 2C) . Using ESP, an RNA isolation step was performed (in combination with a reduced 30 second elongation amplification step) for comparison to the whole cell input (in combination with the published TILDA 4 minute elongation amplification step) on samples of HIV-infected cell lines spiked into an increasing background population. While detection of tat/rev msRNA from whole cells saw a multiple-fold reduction across increasing background cells, an ESP RNA input eliminated the sensitivity decay in detection as background increased, in up to 150 000 background cells (maximum quantity tested). In comparison, the positive detection signal (as defined by calculation of a cycle threshold using the Lightcycler 480 Second Derivative Maximum function) from the whole cell inputs was delayed as background increased until, in a background of 150 000 cells, no positive events were detected (Fig. 2C) .
As ACH-2 cells respond with increased HIV production following induction with PMA as measured by extracellular virus levels (ESI, † Fig. S3 ), we tested to determine (1) whether this change could be detected in intracellular tat/rev msRNA levels and (2) whether either whole cells or ESP RNA TILDA inputs might be more sensitive in detecting a response to induction. To evaluate, ACH-2 cells were either cultured for 12 hours in induction media containing 10 mM PMA or culture media. Ten cells from each population were then placed in a background of 1000 cells for TILDA (RNA 30 second elongation cycles; whole cells 4 minute elongation cycles), either as whole cells or ESP isolated RNA. Compared to the non-induced sample, both sample inputs saw an increase in tat/rev msRNA (Fig. 2D) . However, the ESP RNA input resulted in the detection of a much greater fold change in tat/rev msRNA detection as well as less sample-to-sample variability compared to the whole cells improving the case for RNA as a more sensitive input for TILDA.
RNA TILDA comparison and validation with contrived samples
In order to validate ESP RNA TILDA (with 30 second elongation cycles) to whole cell TILDA (4 minute elongation cycles), a direct comparison was performed with contrived samples. Approximately 1-15 ACH-2 cells were spiked into a background of either Hut78 cells or healthy donor PBMCs (248 000 cells). These cells were then distributed across 32 total wells consisting of eight wells each of 18 000 cells, 9000 cells, 3000 cells, and 1000 cells following the published TILDA dilutions; this enabled the creation of both ACH-2-positive wells and ACH-2-negative wells for analysis. For the ESP RNA TILDA, these cells were distributed (8 wells each of 18 000, 9000, 3000, or 1000 cells) into a standard 96-well plate, RNA extracted with ESP, and the extracted RNA transferred to a PCR plate. Using the contrived samples of ACH-2 cells, the number of positive events detected in each method correlated well (Fig. 3A) . Thus this approach served to support RNA as an alternative input to whole cells. While both inputs resulted in similar events detected, on average, the RNA-based TILDA detected positive events B5 cycles (corresponding to a 32-fold increase in relative RNA signal) earlier than the whole cell positive events (calculated based on the average cycle threshold of positive events obtained within each experiment across 10 experiments).
Due to the rarity of these cells in patients, ultimately an increased cell capacity would benefit the assay's clinical utility. Thus, the whole cell TILDA and ESP RNA TILDA were compared using high background samples consisting of 50 000 cells per well (Fig. 3B) . Again, ACH-2 cells were spiked into identical samples and divided amongst the wells for either direct detection (whole cell TILDA) or ESP RNA TILDA. While the previous comparison resulted in nearly identical results across inputs (Fig. 3A) , when background increased, ESP RNA TILDA shifted from the nearly 1-to-1 correlation observed in lower background, consistently detecting more positive events (Fig. 3B) . With the exception of some of the lower input samples (i.e., 2 or fewer events detected per assay), ESP TILDA consistently detects more events, suggesting improved sensitivity under increasing background. Notably, this is observed in samples likely high for tat/rev msRNA, as the cells constitutively produce HIV in the absence of induction (PMA), in contrast to truly latent events. As opposed to the whole cell samples, the ESP RNA TILDA detected more events in 9/13 samples (1 sample identical results; 3 samples less) when detecting from a background of 50 000 cells. Additionally, within the events detected, again ESP RNA TILDA, on average, detected positive events cycles earlier. While highly idealized samples consisting of constitutively HIV producing cells, RNA is already demonstrating potential gains in both sensitivity detecting events as well as improved detection in high background samples, even with greatly reduced thermocycling times. In patient samples, prevalence of tat/rev msRNA is only likely to decrease, highlighting the benefits of integrating RNA.
Patient sample comparison
The potential advantages beyond cell lines with ESP RNA TILDA were next evaluated on HIV-positive patients. The ESP RNA TILDA (30 second elongation cycles) was compared to the whole Fig. 3 Head-to-head comparison of an ESP RNA input and a whole cell input for detection by TILDA using contrived samples of HIV-infected ACH-2 cells in a background population identical to the published TILDA (18 000 to 1000 cells per well). Whole cell detection was done using 4 minute preamplification elongation cycles while the RNA was detected after 30 second pre-amplification elongation cycles. The number of positive events were then counted and compared across methods (n = 10 plotted data points). The additional noted point (empty circle) was characterized as an outlier (fell outside the data's linear regression 95% confidence interval) (A). A direct comparison experiment was then performed in an increased background where ACH-2 cells were spiked at low number in a background population of 50 000 cells per well. Here, the ESP RNA samples consistently detected more positive events in the increased background (9/13 samples) (n = 13) (B). Dashed lines represent a hypothetical one-to-one correlation.
cell TILDA (4 minute elongation cycles) input on PBMCs isolated from an HIV-positive patient using the established TILDA cell quantities (i.e., 18 000 cells per well down to 1000 cells per well). On average, ESP RNA resulted in a higher frequency of tat/rev msRNA events detected from an identical number of inputted cells (average fold increase of 1.5) (Fig. 4) . In samples obtained from healthy controls (n = 3), both assays (whole cell and ESP RNA) resulted in no positive events across the dilution series (i.e., 8 wells each of 18 000, 9000, 3000, and 1000). While the contrived samples maintained very similar detection of events across methods within the cell quantities of the published assay (up to 18 000 cells), here we see ESP resulting in a larger quantitation of the reservoir consistently in patients, suggesting ESP RNA may increase sensitivity of the assay.
Discussion
In order to facilitate the next generation of HIV monitoring and enable treatments targeting the viral reservoir, assays to quantify the reservoir are required to provide a benchmark of treatment success and patient eligibility for ART interruption. While numerous assays have been introduced (DNA-based assays, QVOA), variation across assays remains widespread, likely due to quantification of a range of analytes with varying relevance (e.g., HIV DNA, integrated DNA by alu-PCR, viral outgrowth). Recently, Procopio et al. (2015) introduced tat/rev induced limiting dilution assay (TILDA), which provides a new analyte, tat/rev msRNA, as a metric for reservoir quantification. A step beyond HIV DNA and a step short of detecting production of infectious virus, TILDA is poised to increase the specificity of HIV DNA-based assays, detecting a further downstream target, while retaining their attractive simplicity and greater reproducibility compared to QVOA.
While TILDA is poised to provide a new metric for reservoir quantification, upstream sample processing and purification could improve the assay to increase assay sensitivity and capacity, two key factors in detecting rare events. ESP TILDA offers the following advantages: (1) increased sensitivity in detection of rare events through use of a purified input material additionally enabling the interrogation of a larger number of patient cells; (2) decreased RT-PCR thermocycler usage by 88%; (3) maintained simplicity of original TILDA assay via implementation of an RNA isolation process, ESP, which is optimized for simplicity and speed. While the published TILDA advertised its simplicity in not requiring RNA extraction, we propose that the reliance on whole cells limits both TILDA's capacity and sensitivity along with increased assay duration. As TILDA requires a nested PCR reaction following reverse transcription, the assay faces limitations well known to this field, namely input sample impacts results. Traditional inputs for these reactions are purified RNA and/or DNA, as background material is often detrimental to reaction kinetics impacting sensitivity or detection altogether. [20] [21] [22] A whole cell input introduces significant background material, which impair reaction kinetics and detection capabilities compared to a reaction utilizing purified nucleic acid. Historically, RNA extractions have been tedious, requiring extensive time especially at the scale required by TILDA (i.e., numerous independent isolations). However, the development of beadbased RNA extraction kits combined with exclusion-based sample preparation, a bead isolation technology, allows users to rapidly preform RNA isolations, 8 isolations at a time, using either an automated or handheld system. The addition of RNA isolation requires less than 1 hour to perform 96 isolations. Additionally, by transitioning to a RNA input, pre-amplification elongation cycle time is reduced to 1/8 of the published time (96 minutes to 12 minutes), reducing thermocylcer usage by 84 minutes. While some hands-on time is required to perform RNA extractions (unless automated), the required RNA extraction time using the presented multiplexed fashion, remains well below the thermocycling time saved (estimated at 40 minutes per 96-well plate). The timesaving, paired with improved sensitivity, presents an opportunity for RNA-based TILDA.
In comparing RNA to whole cell inputs in contrived samples, RNA presents significant advantages in stronger, often more consistent detection of tat/rev msRNA; thereby providing improved sensitivity in detecting either subtle changes or rare events. Significantly, a RNA input allows users to scale up the number of cells interrogated per well. Increasing assay capacity will become increasingly critical in the clinic as reservoir targeted treatments will deplete the reservoir, requiring the evaluation of larger cell quantities to monitor successful treatment. Ultimately, this may push the reservoir beyond the 744 000 cell events interrogated per plate. While conceivably TILDA could be performed using multiple plates or maximizing input to 18 000 cells in every well (maximum of 1.728 million events per plate), multiple plates would only increase assay time and equipment demands of the assay. Beyond this capacity, a whole cell input may suffer from reduced reaction sensitivity observed in contrived samples as background cell number increased. The phenomenon of decreasing signal with increasing background was reduced significantly by an ESP RNA input (Fig. 2 ) Fig. 4 Comparison of detection of tat/rev msRNA from PBMCs collected from HIV-positive donors using both the published whole cell TILDA (4 minute elongation cycles) and the ESP RNA TILDA (30 second elongation cycles). In 6/8 patients, the ESP RNA TILDA resulted in an increased change in reservoir quantitation compared to the whole cell TILDA (two samples demonstrated no change). Dashed lines represent a one-to-one correlation.
speaking to the significant advantages RNA could provide in scaling up TILDA with expanding quantitative needs. Additionally, large single well inputs could have the potential in future TILDA applications if, to simplify processing, PBMCs rather than T-cells are evaluated; the switch to PBMCs would similarly require more events to be utilized. Additionally, wells of high cell number could be used to rapidly screen patients to get baseline readout for their reservoir (i.e., frequency of events is 1 in 100 000 vs. 1 in 10 million), before performing a full-scale assay to determine the sensitivity needed for each patient. As reservoir sizes vary greatly and currently are fairly unpredictable, screening patients to get a relative frequency would provide clinicians with the information necessary to scale the TILDA capacity to assay as many or as few cells as necessary (i.e., evaluate 500 000 events or 10 million or more events).
The published TILDA demonstrated a new analyte and assay on which to benchmark the HIV viral reservoir. We believe the presented modifications and method with which to integrate RNA inputs provide substantial benefits on the published assay expanding capacity, which will be required as developing treatments continually diminish the reservoir size. RNA inputs demonstrate clear potential in expanding inputs, which could be used to both scale up the input without requiring multiple TILDA plates or enable qualitative screening, to predict reservoir size and ensure adequate cells are inputted into the quantitative assay.
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